D-Wave Quantum stock slides after Quantum Circuits deal closes and a 10.4 million-share resale filing hits

D-Wave Quantum stock slides after Quantum Circuits deal closes and a 10.4 million-share resale filing hits

NEW YORK, Jan 20, 2026, 20:14 EST — Market closed.

  • Shares of D-Wave Quantum slipped 6.2%, ending Tuesday at $27.04
  • A filing registered as many as 10.43 million shares for resale linked to the Quantum Circuits acquisition
  • Investors are on alert for selling pressure and new insights at D-Wave’s Qubits conference next week

D-Wave Quantum Inc. shares dropped 6.2% on Tuesday, ending the day at $27.04. The quantum computing firm completed its acquisition of Quantum Circuits and filed a resale registration that might increase shares available for trading. The stock fluctuated between $25.96 and $28.48, with roughly 51 million shares traded.

The company submitted a prospectus supplement dated Jan. 20, outlining the resale of up to 10,430,444 shares by selling stockholders. It clarified that the company itself will not gain any proceeds from these sales. The filing also noted that the selling stockholders may sell “any, all or none” of the shares, leaving investors uncertain about how quickly these shares could hit the market. (SEC)

In a separate filing, D-Wave confirmed it closed the Quantum Circuits deal on Jan. 20, shelling out $250 million in cash plus 10,430,444 shares of common stock, pending adjustments. At Tuesday’s close, those shares were valued at roughly $282 million, bringing the total upfront price to about $532 million before any tweaks. The company also warned of integration risks and noted its stock could drop if the anticipated benefits take longer to materialize. (SEC)

Quantum computing stocks mostly slipped during the session. IonQ finished close to unchanged, but Rigetti Computing dropped roughly 2%, and Quantum Computing Inc fell nearly 6%, highlighting the sector’s volatile moves.

The deal brings a gate-model quantum program onto D-Wave’s existing “annealing” platform. Unlike annealing machines, which focus on optimization tasks like scheduling and routing, gate-model systems are designed to execute a broader range of algorithms through sequences of quantum operations.

D-Wave said Quantum Circuits brings error-corrected superconducting gate-model technology and a “dual-rail” qubit approach designed to simplify error correction. CEO Alan Baratz called the acquisition a “watershed moment.” Rob Schoelkopf, co-founder of Quantum Circuits and now D-Wave’s chief scientist, said the deal gives the company “a decisive advantage” in gate-model quantum computing. D-Wave plans to launch its first gate-model system in 2026 and highlighted its Qubits 2026 conference, set for Jan. 27-28 in Boca Raton, Florida. (SEC)

Per the registration rights agreement signed at closing, D-Wave must file a shelf registration statement—or a prospectus supplement to an existing shelf—within three business days. However, the company can delay if trading blackout periods apply or if filing would reveal material nonpublic information. (SEC)

QBTS holders face a near-term risk as the market shifts attention away from the technology story and zeroes in on the mechanics: integration expenses, cash burn following a $250 million cash payout, and the potential rush by ex-Quantum Circuits shareholders to offload registered shares amid volatile trading.

U.S. trading picks up again Wednesday, with investors eyeing potential selling linked to the newly registered shares and any fresh updates on the gate-model roadmap timeline. The next big date on the calendar is the Qubits 2026 event, slated for Jan. 27-28.

Stock Market Today

  • Intuitive Surgical Shares Show Overvaluation Risks Amid Price Slump
    January 20, 2026, 8:40 PM EST. Intuitive Surgical's (ISRG) stock has fallen 6.1% over the past week and 12.7% in the last year, despite strong multi-year gains exceeding 100%. The shares closed at $527.44, but a Discounted Cash Flow (DCF) analysis values the company at around $352.31 per share, indicating a potential overvaluation of nearly 50%. The company, a major player in robotic-assisted surgery, faces investor scrutiny amid evolving medical technology trends and competitive pressures. Traditional metrics like the Price-to-Earnings (P/E) ratio provide additional insight into valuation challenges. These mixed signals highlight a reassessment phase for investors evaluating ISRG's forward-looking growth and current pricing.
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next
Previous Story

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

Go toTop